How to position for the next wave of AI-led scientific breakthroughs

Artificial intelligence is no longer confined to text generation, but is now transforming scientific research, offering lucrative investment prospects in various sectors, asserts UBS Wealth Management. The turning point came with OpenAI's recent mathematical proof concerning the Navier-Stokes equations, a fluid dynamics quandary dating back centuries and a Millennium Prize Problem.

Utilizing 10,000 autonomous AI agents operating concurrently for 88 hours, OpenAI managed to pinpoint a situation where fluid forces escalate infinitely, culminating in a mathematical impasse, before ultimately substantiating the proof via Lean, a system designed for machine-verified mathematical validation. This breakthrough could reverberate across diverse domains, from aviation aerodynamics to nuclear fusion.

Three sectors appear particularly promising in terms of commercial viability: drug development, fusion energy, and advanced materials. In the pharmaceutical industry, AI-powered multi-agent systems can simulate thousands of protein permutations in the cloud, evaluating attributes like toxicity, blood circulation stability, and manufacturing resilience prior to any laboratory intervention.

Currently, over 170 AI-engineered compounds are under development or in clinical trials, including Phase III evaluations. AI could also assume a pivotal role in nuclear fusion by aiding in the stabilization of highly turbulent plasma. Leveraging reinforcement-learning systems, these agents can scrutinize reactor data, forecast plasma disruptions approximately 200 milliseconds prior to their occurrence, and adjust magnetic coils thousands of times per second.

The commercial fusion enterprise stands to gain from the electricity-hungry AI infrastructure, manufacturing, utilities, and grid infrastructure.

The underlying investment thesis revolves around AI assuming the role of an automation tool in scientific research, rather than merely producing content. Companies with exposure to AI infrastructure, pharmaceuticals, industrial materials, and utilities could reap the benefits as these technologies transition from the laboratory to commercial applications.